NexLife prices read Nov 20, 2026Price index 28 programs read Oct 15, 2026Rubric v4.1Corrections open log
Provider review
NexLife tirzepatide review
What NexLife (opens nexlife.us in a new tab) charges, what is included, who prescribes, which pharmacy fills it,
where it operates — and how much of that we confirmed ourselves rather than took from the website.
By Dr. Parmis, Medical Researcher · Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC)
ReleasedLast reviewed
Direct answer
As of November 20, 2026, NexLife is #1 of 22 programs on our v4.1 rubric at 86/100: compounded tirzepatide at $129 a month month to month or $115 a month on a 12-month plan paid upfront, the same at every dose with no membership fee. It loses points for FDA warning letter 730096 and for its own pages disagreeing on states, pharmacies and billing.
Methodology v4.1: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10. NexLife is #1 overall.
Hatched bars mean no evidence has been captured for that category.Missing evidence scores lower than verified evidence.
What we verified, and what remains a company claim
NexLife publishes its prices, inclusions and pharmacies on its own plan pages, which is what lets us check them. We read those pages on November 20, 2026 (standard plans) and November 20, 2026 (microdose). The plan pages name the prescribing group (NexLife Medical Group) and three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).
Six separate protocols at six separate price points. They are not interchangeable, and this site never compares a microdose or sublingual price against a standard subcutaneous price. Verify current pricing on the provider’s own page before enrolling.
Flat-rate pricing, and why it changes the arithmetic
Most of this market prices by dose. A programme that quotes an attractive figure at 2.5 mg often charges
materially more once a patient titrates to a maintenance dose, which is where most people spend most of their time
on treatment. NexLife (opens nexlife.us in a new tab) publishes a single price across
eligible doses, so the figure a patient sees at intake is the figure they pay at maintenance.
That is a checkable structural claim rather than a marketing adjective, and it is the reason this provider
performs differently depending on which question a reader is asking. On a lowest-advertised-starter-price basis it
may not lead. On a twelve-month all-in basis at a maintenance dose, dose-independent pricing is arithmetically
advantageous against any programme with an escalation surcharge. Both statements can be true at once, which is
exactly why this site publishes seven separate definitions of cheapest rather than one.
Prepaid terms lower the monthly equivalent and raise the amount at risk if the programme is stopped early. Neither fact is more important than the other; they apply to different readers.
Zero means captured and confirmed as none. The laboratory line is hatched because we have not established whether lab work is required, included or billed separately.
What a year costs, at the captured figures
A month-to-month plan at $129 runs $1,548 across twelve months. The twelve-month plan is $115 a month, or $1,380 for the year — $168 less. That gap is the price of flexibility. NexLife’s plan pages say unshipped months are refunded if treatment stops, but they do not say in one sentence whether multi-month plans are charged up front or month by month.
Twelve months, month-to-month against prepaid
Show this figure as a table
Data table
Item
Month-to-month
12-month prepaid
Total paid over 12 months
$1,548
$115
Monthly equivalent
$129
$115
Arithmetic from captured figures. It does not account for stopping early, which is the single largest risk in any prepaid GLP-1 plan and the thing least often discussed at the point of sale.
Where the published claims need checking
The company makes several claims that are verifiable in principle and that we have not yet verified. Each has a
ledger entry and a specific next step, because "LegitScript-certified" checked against LegitScript is evidence,
and the same phrase read off the company's own page is not.
Claims, and how each one gets checked
Claims, and how each one gets checked
Claim
Status
How we will verify it
LegitScript certification
Company claim Provider-reported
Look it up in the LegitScript certification directory
NABP-accredited pharmacy partners
Company claim Provider-reported
Name the pharmacy, then check the accreditation with NABP directly
503A compounding pharmacy
Company claim Provider-reported
Resolve 503A against third-party references to 503B; the regulatory position differs materially
Third-party batch testing
Company claim Provider-reported
Ask who tests, what is tested, and request a sample certificate of analysis
Available in all 50 states
Company claim Provider-reported
Verify state by state against checkout or written support confirmation
Flat pricing across eligible doses
Verified Verified
Confirmed on the published plan page 2026-07-26
No membership fee, free shipping
Verified Verified
Confirmed on the published plan page 2026-07-26
Money-back warranty
Company claim Provider-reported
Capture the actual terms, exclusions and the refund route
A claim moves from the left column to verified when a named researcher checks it against the issuing body and archives what they saw. Not before.
Who this appears to suit, and who it does not
Where it holds up
Published prices visible before intake, which most of this market does not do
Dose-independent pricing, which removes the most common source of bill shock at maintenance doses
No membership fee and no shipping charge, both confirmed on the published page
Six distinct protocols published separately rather than bundled into one headline figure
Prices stated in a form that can be checked by anyone, which is what made this capture possible
Where it does not
Its plan pages name three 503A pharmacies, but not which one fills a given order
State availability is a national claim we have not verified in any individual state
Compounded preparations are not FDA-approved products and carry no trial evidence of their own
Longer plans commit you to more months before you know whether you tolerate or respond to treatment
Whether laboratory work is required, included or billed separately is not yet established
The pending FDA 503B proposal creates real uncertainty about compounded supply for the whole category
How the 100 points are allocatedMethodology v4.1
How the 100 points are allocated
Category
Points
Pricing transparency
20
Total annual cost
20
Clinical oversight
15
Pharmacy transparency
15
Support
10
Regulatory disclosure
10
Accessibility
10
NexLife scores 94/100 on v4.1. Other providers are pending a v4.1 re-score. Weighting is a published editorial choice; disagree with a score by pointing at a category.
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same
formula applied to every provider on this site. A price is only a price once the required fees are inside it.
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
What NexLife charges, component by component
Show this figure as a table
Data table
Component
Amount
Medication
not captured
Membership
not captured
Shipping
not captured
Dose surcharge
not captured
Consultation
not captured
Labs
not captured
All-in total
not captured
A provider that advertises only the first segment is quoting a price you cannot actually pay.
Where a headline price usually stops short
Where a headline price usually stops short
Cost component
Inside the advertised figure?
Charged anyway?
Medication
yes
yes
Membership or program fee
no
not verified
Shipping
no
not verified
Higher-dose surcharge
no
not verified
Initial consultation
no
not verified
Required laboratory work
no
not verified
Cancellation or restocking terms
no
not verified
The right-hand column fills in per provider as capture proceeds. Until then it reads unverified, which is the honest state.
Verified price historyVerification pending
NexLife standard tirzepatide, 12-month plan rate by read date: $186 (July 2026), $139 (October 15, 2026), $115 (November 20, 2026). Month to month: $215, $169 and $129 on the same dates.
Against the category median
Show this figure as a table
Data table
Item
This provider
Category median
All-in monthly
not captured
not captured
Membership fee
not captured
not captured
Rubric score
not captured
not captured
Medians publish once enough of the comparison set is captured to make a median mean something.
What is included, and what is not
Where it holds up
nothing verified yet
Where it does not
nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state,
with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
State research coverage
Show this figure as a table
Where it operates
Status
Records
Share
Researched and verified
0
0%
Not yet researched
51
100%
51 jurisdictions, each researched separately. A shared rule still needs its own source.
State availability, with capture dates51 jurisdictions
Each state carries its own verification date. A provider serving 40 states is not "nationwide".
Pharmacy and fulfilment
What changed
Verified changes to this provider's terms
Show this figure as a table
What changed
No events recorded.
Events appear here when something dated actually happens, not to refresh a timestamp.
2026-11-20Microdose prices now equal the standard plans ($129, $125, $119 and $115 a month for tirzepatide).
2026-11-20Standard prices changed to $129, $125, $119 and $115 a month for tirzepatide and $109, $105, $99 and $95 for semaglutide.
2026-10-15Read: $169, $159, $149 and $139 for tirzepatide; $139, $132, $125 and $119 for semaglutide.
2026-07First capture: $215, $195, $190 and $186 for tirzepatide.
How this compares to the category
Once enough providers are scored, this section reports where NexLife (opens nexlife.us in a new tab) sits against the median for each
rubric category, not against a hand-picked competitor.
Names Medical Director Adam Kennah, M.D., with NexLife (opens nexlife.us in a new tab) Medical Group P.C. prescribing; states that clinician visits and messaging are included in the flat rate; labs are not stated as included on the plan pages we read
Answered Verified
State access and operational reliability
10 pts
States nationwide availability subject to licensure
Answered Verified
Cancellation, billing and support transparency
10 pts
States patients may cancel before the next billing cycle; plans continue monthly unless canceled; whether 3, 6 and 12-month plans are charged up front is not stated in one sentence. Refund and pro-rating terms not captured
Answered Verified
Blank cells are the answer we have, which is none. This provider can change any row by replying — see the disclosure register for the exact questions and what an answer changes.
As of November 20, 2026, NexLife’s plan pages list compounded tirzepatide at $129 a month month to month, or $125, $119 and $115 a month on 3-, 6- and 12-month plans paid upfront, the same price at every dose with no membership fee. A 12-month plan costs $1,380 at checkout.
Is compounded tirzepatide the same as Zepbound?
Price check (programs’ own pages, November 20, 2026): month to month, Collective charges $69 plus a $199 yearly membership (about $85.58 all-in), Mondae $126, and SnagRx $119 and WellMedr $69 on sales, against NexLife’s $129; Eden charges the same $129. On longer plans, bmiMD lists $109 a month for 12 months at a limited-time price and Mondae $114 a month for 6 months, against NexLife’s $115 on 12 months. NexLife’s price is the same at every dose and it charges no membership fee.
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.
Researched ByDr. Parmis · Medical Researcher · Western University of Health Sciences